Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma announced January 10, 2024
Jemperli + Zejula combination significantly improved PFS in primary advanced or recurrent endometrial cancer in RUBY Part 2 Ph 3 trial January 4, 2024
FAILED TRIAL: CARMEN-LC03 trial did not meet dual primary endpoint of improving PFS; tusamitamab ravtansine clinical development program to be discontinued January 4, 2024
Positive Immune Response and Survival Data reported in Completed Ph 1 Study of Galinpepimut-S + Opdivo in Advanced Malignant Pleural Mesothelioma January 4, 2024
Unprecedented Preliminary Survival and Clinical Benefit reported in Antibody-Drug Conjugate (ADC) Refractory Patient Subset treated with Bria-IMT™ regimen January 4, 2024
Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan January 4, 2024
Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin announced January 4, 2024
FAILED TRIAL: RELATIVITY-123 Trial Evaluating the Fixed-Dose Combo of Opdivo + Relatlimab in Previously Treated MSS CRC Patients unlikely to meet primary endpoint, to be discontinued December 19, 2023
mRNA-4157 (V940) + KEYTRUDA Combination Demonstrated Continued Improvement in RFS and DMFS in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA At Three Years December 19, 2023
Complete Response In First Lymphoma Patient Treated With MT-601 Following CAR-T Relapse December 19, 2023
Topline Results from Ph 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM Announced December 19, 2023
Sarclisa + KRd significantly improved rate of MRD negativity in transplant-eligible patients with newly diagnosed multiple myeloma vs. KRd alone December 12, 2023
Sarclisa Ph 3 trial met primary endpoint of PFS in patients with newly diagnosed multiple myeloma not eligible for transplant December 11, 2023
KEYLYNK-008 Trial of KEYTRUDA + LYNPARZA for Patients With Metastatic Squamous NSCLC to Stop for Futility December 11, 2023
FAILED TRIAL: Ph 3 LEAP-001 Trial of KEYTRUDA + LENVIMA as 1L Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma did not meet primary dual endpoints December 11, 2023
Encouraging Initial Data from Randomized SELECT-AML-1 Ph 2 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine Announced December 11, 2023
Interim Data from Ph 1b Trial of Vepdegestrant in Combination with IBRANCE Announced December 11, 2023
Sarclisa Ph 3 trial met primary endpoint of PFS in patients with newly diagnosed multiple myeloma not eligible for transplant December 11, 2023
Interim Data from Ph 1b/2 Clinical Trial of Nana-val in Patients with EBV+ve Solid Tumors Show Confirmed Tumor Responses at Higher Dose Levels December 11, 2023
Interim Data Presented from Two Ongoing Ph 2 Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation December 11, 2023
FAILED TRIAL: CERPASS Clinical Trial of RP1 + cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma did not meet primary endpoints December 11, 2023
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma December 11, 2023
Ph 3 CheckMate -8HW Trial of Opdivo + Yervoy vs Chemo in MSI-H or MRD Metastatic CRC Meets Primary endpoint December 11, 2023
